[go: up one dir, main page]

DE69619125D1 - Amino substituierte pyrimidinen und triazinen - Google Patents

Amino substituierte pyrimidinen und triazinen

Info

Publication number
DE69619125D1
DE69619125D1 DE69619125T DE69619125T DE69619125D1 DE 69619125 D1 DE69619125 D1 DE 69619125D1 DE 69619125 T DE69619125 T DE 69619125T DE 69619125 T DE69619125 T DE 69619125T DE 69619125 D1 DE69619125 D1 DE 69619125D1
Authority
DE
Germany
Prior art keywords
triazines
amino substituted
substituted pyrimidines
pyrimidines
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69619125T
Other languages
English (en)
Other versions
DE69619125T2 (de
Inventor
R Webb
J Moran
R Mccarthy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neurocrine Biosciences Inc
Original Assignee
Janssen Pharmaceutica NV
Neurocrine Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV, Neurocrine Biosciences Inc filed Critical Janssen Pharmaceutica NV
Publication of DE69619125D1 publication Critical patent/DE69619125D1/de
Application granted granted Critical
Publication of DE69619125T2 publication Critical patent/DE69619125T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C07D239/49—Two nitrogen atoms with an aralkyl radical, or substituted aralkyl radical, attached in position 5, e.g. trimethoprim
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
DE69619125T 1995-10-17 1996-10-15 Amino substituierte pyrimidinen und triazinen Expired - Fee Related DE69619125T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US568795P 1995-10-17 1995-10-17
PCT/EP1996/004478 WO1997014684A1 (en) 1995-10-17 1996-10-15 Amino substituted pyrimidines and triazines

Publications (2)

Publication Number Publication Date
DE69619125D1 true DE69619125D1 (de) 2002-03-21
DE69619125T2 DE69619125T2 (de) 2002-09-26

Family

ID=21717189

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69619125T Expired - Fee Related DE69619125T2 (de) 1995-10-17 1996-10-15 Amino substituierte pyrimidinen und triazinen

Country Status (18)

Country Link
US (1) US6288060B1 (de)
EP (1) EP0863882B1 (de)
JP (1) JPH11513678A (de)
KR (1) KR19990045744A (de)
AR (1) AR004221A1 (de)
AT (1) ATE212987T1 (de)
AU (1) AU703096B2 (de)
CA (1) CA2229710A1 (de)
DE (1) DE69619125T2 (de)
DK (1) DK0863882T3 (de)
ES (1) ES2172681T3 (de)
MY (1) MY113945A (de)
NO (1) NO310771B1 (de)
NZ (1) NZ320227A (de)
PT (1) PT863882E (de)
TW (1) TW378206B (de)
WO (1) WO1997014684A1 (de)
ZA (1) ZA968732B (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6191131B1 (en) 1997-07-23 2001-02-20 Dupont Pharmaceuticals Company Azolo triazines and pyrimidines
US7094782B1 (en) 1996-07-24 2006-08-22 Bristol-Myers Squibb Company Azolo triazines and pyrimidines
US6313124B1 (en) 1997-07-23 2001-11-06 Dupont Pharmaceuticals Company Tetrazine bicyclic compounds
US6124289A (en) * 1996-07-24 2000-09-26 Dupont Pharmaceuticals Co. Azolo triazines and pyrimidines
US6060478A (en) * 1996-07-24 2000-05-09 Dupont Pharmaceuticals Azolo triazines and pyrimidines
DE19837387A1 (de) * 1998-08-18 2000-02-24 Aventis Res & Tech Gmbh & Co 3'-Desoxypentopyranosyl-Nucleinsäure, ihre Herstellung und Verwendung
WO2000049001A2 (en) * 1999-02-16 2000-08-24 E.I. Du Pont De Nemours And Company Phenoxy-, phenylthio-, phenylamino-, benzyloxy-, benzylthio- or benzylaminopyrimidine insectidices and acaricides
US6432989B1 (en) 1999-08-27 2002-08-13 Pfizer Inc Use of CRF antagonists to treat circadian rhythm disorders
PL354784A1 (en) 1999-09-30 2004-02-23 Neurogen Corporation Certain alkylene diamine-substituted heterocycles
US6525067B1 (en) * 1999-11-23 2003-02-25 Pfizer Inc Substituted heterocyclic derivatives
AU2001234180A1 (en) * 2000-02-25 2001-09-03 Japan Tobacco Inc. Benzamide derivative and use thereof
EP1301490A2 (de) 2000-07-18 2003-04-16 Neurogen Corporation 5-substituierte 2-aryl-4-pyrimidinone
AU8447301A (en) 2000-09-19 2002-04-02 Sumitomo Chemical Co Pyrimidine compounds and their use
CA2423156A1 (en) 2000-09-21 2002-03-28 Bristol-Myers Squibb Company Substituted azole derivatives as inhibitors of corticotropin releasing factor
US20030055249A1 (en) * 2001-07-17 2003-03-20 Fick David B. Synthesis and methods of use of pyrimidine analogues and derivatives
US6872827B2 (en) * 2002-04-26 2005-03-29 Chembridge Research Laboratories, Inc. Somatostatin analogue compounds
CA2527079A1 (en) * 2003-05-29 2005-01-06 Synta Pharmaceuticals, Corp. Heterocyclic compounds for preventing and treating disorders associated with excessive bone loss
US20060024661A1 (en) * 2003-07-30 2006-02-02 The Regents Of The University Of California Modulation of CRF potentiation of NMDA receptor currents via CRF receptor 2

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2595697B1 (fr) * 1986-03-13 1988-07-08 Rousselot Cie Derives de benzyl-pyrimidine, leur procede de preparation ainsi que les compositions en contenant
FR2692893B1 (fr) 1992-06-24 1994-09-02 Sanofi Elf Dérivés alkylamino ramifiés du thiazole, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent.
CN1142817A (zh) * 1993-10-12 1997-02-12 杜邦麦克制药有限公司 1n-烷基-n-芳基嘧啶胺及其衍生物
TW574214B (en) * 1994-06-08 2004-02-01 Pfizer Corticotropin releasing factor antagonists

Also Published As

Publication number Publication date
ATE212987T1 (de) 2002-02-15
EP0863882A1 (de) 1998-09-16
US6288060B1 (en) 2001-09-11
AU7292996A (en) 1997-05-07
KR19990045744A (ko) 1999-06-25
NO310771B1 (no) 2001-08-27
NO981623D0 (no) 1998-04-08
TW378206B (en) 2000-01-01
ES2172681T3 (es) 2002-10-01
CA2229710A1 (en) 1997-04-24
AR004221A1 (es) 1998-11-04
NO981623L (no) 1998-06-09
PT863882E (pt) 2002-07-31
AU703096B2 (en) 1999-03-18
JPH11513678A (ja) 1999-11-24
EP0863882B1 (de) 2002-02-06
NZ320227A (en) 1998-11-25
MY113945A (en) 2005-12-14
DE69619125T2 (de) 2002-09-26
WO1997014684A1 (en) 1997-04-24
DK0863882T3 (da) 2002-05-06
ZA968732B (en) 1998-04-16

Similar Documents

Publication Publication Date Title
DE69738197D1 (de) Azolotriazine und pyrimidine
FI972087L (fi) Dihydropyrimidiineja ja niiden käyttöjä
DE69619125D1 (de) Amino substituierte pyrimidinen und triazinen
DE69627188D1 (de) Brille und brillenfassung
DE69828963D1 (de) Wirstoffabgabe und gentherapiesystem
DK0817775T3 (da) Quinazolinderivater
DK0823900T3 (da) Quinazolinderivater
BR9608155A (pt) Amino fenil uracilas substituídas
DE59802439D1 (de) Spiroverbindungen und deren verwendung
DE69513307D1 (de) Zusammensetzung und verwendung
BR9508539A (pt) Derivado de triazina e medicamento
BR9611570A (pt) Derivados de triazina
GB9617322D0 (en) Triazine derivatives and their use
ZA972553B (en) Aryloxy-and arylthio- substituted pyrimidines and triazines and derivatives thereof
DE69835007D1 (de) Entkoffeinierte mate-extrakte und deren verwendung
FI974517A7 (fi) Suodatin ja säätöelin
DE59810405D1 (de) Spiroverbindungen und deren verwendung
DE69804320D1 (de) Kraftabgängige detektoren und systemen
BR9609671A (pt) Amino uracilas substituídas
NO990264D0 (no) Azolotriaziner og -pyrimidiner
DE69617576D1 (de) Grundierungszusammensetzung und optischer Gegenstand
DE69614491D1 (de) 5HT1Dalpha und 5HT2A Ligande
DE69619355D1 (de) Peripheriemodul und Mikroprozessorsystem
EP0866708A4 (de) Dihydropyrimidine und deren verwendung
ATA38095A (de) Sicherheitsbeschlag sicherheitsbeschlag

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: NEUROCRINE BIOSCIENCES, INC., SAN DIEGO, CALIF., U

8339 Ceased/non-payment of the annual fee